| Long name: |
C9a/C9 Primary Polyclonal Antibody |
| Also known as: |
C9a/C9 PAb |
| Category: |
Primary Antibodies |
| Conjugation: |
Unconjugated |
| Target Antigen: |
C9a/C9 |
| Specificity: |
This is a highly specific antibody against C9a/C9 |
| Modification(s): |
None |
| Modification site(s): |
Unmodified antibody |
| Clonality: |
Polyclonal antibody |
| Clone number: |
Polyclonal antibody |
| Concentration: |
1ug per 1ul |
| Source: |
This antibody was obtained by immunization of the host with KLH conjugated synthetic peptide derived from human Complement component C9a |
| Tested Applications: |
IF(IHC-P), IHC-P, WB |
| Recommended dilutions: |
IF(IHC-P)(1:50-200), IHC-P(1:100-500), WB(1:100-1000) |
| Cross reactivity: |
Human |
| Cross reactive species details: |
not every possible cross-reactivity is known, Due to limited amount of testing and knowledge |
| Background of the target antigen: |
C6, C7 and C8, C9 binds to the membrane associated C5b-8 protein, C9 is a part of the membrane attack complex (MAC), Molecules can then diffuse freely through this transmembrane channel, The MAC forms upon complement system activation by invading pathogenic bacteria and consists of the four major complement proteins: C5b, These complement proteins bind to the outer surface of the plasma membrane of the invading cell, These polymerized C9 molecules form a ring structure in the membrane, an important component of the immune system, causing cell lysis and destruction of the invading bacterial cell, which leads to the circular polymerization of 12-18 C9 molecules, C9 is a plasma protein synthesized in the liver and monocytes consisting of a single polypeptide chain |
| Purification method: |
This antibody was purified via Protein A |
| Storage conditions: |
50% glycerol and 0, Store at -20°, 09% sodium azide, C for up to 1 year, Keep the antibody in aqueous buffered solution containing 1% BSA |
| Synonym names: |
C9, C9 deficiency, C9 deficiency with dermatomyositis, CO9_HUMAN, Complement component 9, Complement component 9 deficiency, Complement component C9a, Complement component C9a, C9a |
| Properties: |
C, C for long term storage and for short term at + 5°, If you buy Antibodies supplied by Bioss Primary Unconjugated Antibodies they should be stored frozen at - 24° |
| Gene target: |
C9a/C9 |
| Short name: |
C9a/C9 Antibody |
| Technique: |
antibodies against human proteins, antibodies for, Antibody |
| Alternative name: |
C9a/complement component 9 (Antibody to) |
| Alternative technique: |
antibodies |
| Alternative to gene target: |
ARMD15 and C9D, C9 and IDBG-128081 and ENSMUSG00000022149 and 12279, C9 and IDBG-17892 and ENSG00000113600 and 735, C9 and IDBG-629942 and ENSBTAG00000016149 and 526766, Extracellular, alternative pathway and biological process this GO :0006958 and complement activation, classical pathway and biological process this GO :0019836 and hemolysis by symbiont of host erythrocytes and biological process this GO :0030449 and regulation of complement activation and biological process this GO :0045087 and innate immune response and biological process this GO :0070062 and extracellular vesicular exosome and cellular component this GO :0072562 and blood microparticle and cellular component, protein binding, this GO :0005515 and protein binding and molecular function this GO :0005576 and extracellular region and cellular component this GO :0005579 and membrane attack complex and cellular component this GO :0005737 and cytoplasm and cellular component this GO :0005886 and plasma membrane and cellular component this GO :0005887 and integral component of plasma membrane and cellular component this GO :0006957 and complement activation, this GO :0005515 : protein binding, this GO :0005515 : protein binding, complement component 9 |